Key Points
-
GE Vernova reported $35 billion in revenue for 2022, with a backlog of $135.3 billion.
-
CRISPR Therapeutics received FDA approval for its gene-editing therapy Casgevy in late 2023.
-
Taiwan Semiconductor Manufacturing remains a leading player, manufacturing the majority of high-performance chips in the industry.
General Electric’s spinoff, GE Vernova (NYSE: GEV), generated $35 billion in business last year, with a backlog totaling $135.3 billion. The company supplies heavy machinery for energy production, including wind, nuclear, and hydro sectors. It anticipates increased demand as the need for electricity, driven by AI data centers, continues to grow.
CRISPR Therapeutics (NASDAQ: CRSP) received FDA approval for its first gene-editing therapy, Casgevy, targeting transfusion-dependent beta thalassemia, but investors are awaiting further trials before making significant moves. Analysts predict a more than fourfold increase in revenue next year as patient-specific dosing begins.
Taiwan Semiconductor Manufacturing (NYSE: TSM) continues to dominate the chip-making industry, producing a majority of the world’s high-performance semiconductors. Despite some setbacks, industry partnerships are in flux, and demand for semiconductor technology remains high as AI computing needs surge.
